WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA(TM) (sitagliptin), the only DPP-4 inhibitor ...
The head-to-head comparison of four classes of medications assessed multiple metabolic, cardiovascular (CV), and safety outcomes for sulfonylurea glimepiride (Amaryl), the DPP-4 inhibitor sitagliptin ...
(Reuters) - An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...
Merck announced that expanded labeling has been approved for Januvia (sitagliptin), the only DPP-4 inhibitor indicated domestically as an adjunct to diet and exercise to improve glycemic control in ...
KENILWORTH, N.J.-- (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical ...
JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback